Sitafloxacin Sesquihydrate

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H315：Verursacht Hautreizungen.

  H319：Verursacht schwere Augenreizung.

  H335：Kann die Atemwege reizen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Sitafloxacin Sesquihydrate Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  The fluoroquinolone antibacterial agent sitafloxacin hydrate was developed by Daiichi Sankyo and was approved and launched last year in Japan. Sitafloxacin’s mode of action is through inhibition of DNA gyrase and topoisomerase IV. It is indicated for the treatment of inflammatory infections such as laryngopharyngitis, adenoiditis, acute bronchitis, pneumonia, secondary infections due to chronic respiratory lesions, cystitis, pyelonephritis, urethritis, cervicitis, otitismedia, sinusitis, periodontitis, and pericoronitis and jaw inflammation. Due to its broad spectrum of potent antibacterial activity, sitafloxacin is expected to be clinically effective in treating severe cases of bacterial infection, relapse/recrudescence of infection and infections in which resistant bacteria are suspected to be the cause.

• Chemische Eigenschaften

  Off-White Solid

• Verwenden

  Antibacterial

• Verwenden

  Sitafloxacin is a new-generation, broad-spectrum oral fluoroquinolone antibiotic. It is very active against many Gram-positive, Gram-negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, was recently approved in

• Nebenwirkungen

  The most commonly reported adverse reactions include rash, dizziness, headache, diarrhea, loose stool, stomach discomfort, abdominal bloating, abdominal pain, constipation, indigestion, nausea and stomatitis.

• Synthese

  The optically pure fluorocyclopropylamine 111 intermediate was prepared as described in thescheme. Condensation of diphenylmethyl amine 104 with acetaldehyde followed by treatment with trichloromethyl chloroformate in the presence of triethylamine gave N-vinyl carbamoyl chloride 105 in 53% yield. This intermediate was reacted with sodium benzyloxide (generated in situ) to afford N-vinylcarbamate 106 in 82% yield. Fluorocyclopropanation of 106 with zinc¨C monofluorocarbenoid generated from fluorodiiodomethane and diethylzinc provided N-(2-fluorocyclopropyl)carbamate 107 in 90% yield and with a diastereomeric ratio of 93:7 favoring the cis-isomer. Hydrogenolysis of the CBz and the diphenylmethyl groups was accomplished with catalytic 10% palladium on charcoal and was followed by treatment with TsOH to afford dl-108 as its tosylate salt. Acylation of dl- 108 TsOH with l-menthyl chloroformate gave a 1:1 mixture of the diastereomeric carbamate 109 which upon four repeated recrystallizations from hexane/ethyl acetate afforded optically pure 110 in 26% yield. Acidic hydrolysis of 110 furnished 111 as its HCl salt in 88% yield.

  

• Mode of action

  Sitafloxacin inhibits DNA gyrase and topoisomerase IV. These enzymes are involved in bacteria DNA replication, transcription, repair, and recombination. Sitafloxacin has less activity against human topoisomerase II, an enzyme involved in cell growth. According to Akasaka et al. DNA gyrase, consisting of the subunits GyrA and GyrB, has ATP-dependent DNA supercoil-ing activity and is a primary target of quinolones in Gram-negative species, such as Escherichia coli and Neisseria gonorrhoeae. In contrast, topoisomerase IV, consisting of the subunits ParC and ParE, has an essential role in partitioning replicated chromosomes and is more sensitive than DNA gyrase to some quinolones, such as levofloxacin and ciprofloxacin in the Gram-positive species, such as Staphylococcus aureus and Streptococcus pneumoniae[1].

• Einzelnachweise

  [1] Ghebremedhin, B. “Bacterial Infections in the Elderly Patient: Focus on Sitafloxacin.” 2012. 0.

Sitafloxacin Sesquihydrate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(187)Suppliers

163253-35-8, Sitafloxacin Sesquihydrate Verwandte Suche: